368.0K XNAS Volume
XNAS 18 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Mark P. Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
| Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 1,334 | 146,425 (0%) | 0% | - | Ordinary Shares | |
| Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.14 per share. | 31 Jan 2025 | 759 | 145,666 (0%) | 0% | 11.1 | 8,455 | Ordinary Shares |
| Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 3,333 | 148,999 (0%) | 0% | - | Ordinary Shares | |
| Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.14 per share. | 31 Jan 2025 | 1,896 | 147,103 (0%) | 0% | 11.1 | 21,121 | Ordinary Shares |
| Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 3,333 | 150,436 (0%) | 0% | - | Ordinary Shares | |
| Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.14 per share. | 31 Jan 2025 | 1,896 | 148,540 (0%) | 0% | 11.1 | 21,121 | Ordinary Shares |
| Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 1,334 | 0 | - | - | Restricted Stock Units | |
| Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 3,333 | 3,334 | - | - | Restricted Stock Units | |
| Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 3,333 | 6,667 | - | - | Restricted Stock Units | |
| Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 96,377 | 96,377 | - | - | Restricted Stock Units | |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 2,500 | 27,726 (0%) | 0% | - | Ordinary Shares | |
| Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 11.14 per share. | 31 Jan 2025 | 1,258 | 26,468 (0%) | 0% | 11.1 | 14,014 | Ordinary Shares |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 6,667 | 33,135 (0%) | 0% | - | Ordinary Shares | |
| Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 11.14 per share. | 31 Jan 2025 | 3,354 | 29,781 (0%) | 0% | 11.1 | 37,364 | Ordinary Shares |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 5,500 | 35,281 (0%) | 0% | - | Ordinary Shares | |
| Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 11.14 per share. | 31 Jan 2025 | 2,767 | 32,514 (0%) | 0% | 11.1 | 30,824 | Ordinary Shares |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 2,500 | 0 | - | - | Restricted Stock Units | |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 6,667 | 6,667 | - | - | Restricted Stock Units | |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 5,500 | 11,000 | - | - | Restricted Stock Units | |
| Jason Drew Smith | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| Christopher Degnan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2024 | 13,450 | 13,450 | - | - | Restricted Stock Units | |
| Christopher Degnan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2024 | 74,142 | 74,142 | - | - | Employee Stock Option (right to buy) | |
| Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 1,666 | 145,950 (0%) | 0% | - | Ordinary Shares | |
| Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 1,666 | 3,334 | - | - | Restricted Stock Units | |
| Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 13.08 per share. | 09 Sep 2024 | 859 | 145,091 (0%) | 0% | 13.1 | 11,236 | Ordinary Shares |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 3,333 | 6,667 | - | - | Restricted Stock Units | |
| Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 13.08 per share. | 09 Sep 2024 | 1,521 | 25,226 (0%) | 0% | 13.1 | 19,895 | Ordinary Shares |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 3,333 | 26,747 (0%) | 0% | - | Ordinary Shares | |
| Dong Kim | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 2,500 | 5,000 | - | - | Restricted Stock Units | |
| Dong Kim | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 2,500 | 37,753 (0%) | 0% | - | Ordinary Shares | |
| Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2024 | 10,000 | 10,000 | - | - | Stock Option (right ot buy) | |
| Cynthia M. Butitta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2024 | 10,000 | 10,000 | - | - | Stock Option (right ot buy) | |
| Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2024 | 10,000 | 10,000 | - | - | Stock Option (right ot buy) | |
| Stuart Holden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2024 | 10,000 | 10,000 | - | - | Stock Option (right ot buy) | |
| James A. Robinson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2024 | 10,000 | 10,000 | - | - | Stock Option (right ot buy) | |
| Leana S. Wen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2024 | 10,000 | 10,000 | - | - | Stock Option (right ot buy) | |
| Daniel George Wildman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2024 | 10,000 | 10,000 | - | - | Stock Option (right ot buy) | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 10,000 | 20,000 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 13.08 per share. | 10 Jun 2024 | 5,153 | 144,284 (0%) | 0% | 13.1 | 67,401 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 10,000 | 149,437 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.05 per share. | 18 Mar 2024 | 12,000 | 139,437 (0%) | 0% | 14.1 | 168,600 | Ordinary Shares |
| Smith Drew Jason | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 2,500 | 21,324 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| Schoenberg Mark | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 3,333 | 6,667 | - | - | Restricted Stock Units | |
| Schoenberg Mark | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.74 per share. | 31 Jan 2024 | 1,137 | 149,423 (0%) | 0% | 15.7 | 17,896 | Ordinary Shares |
| Smith Drew Jason | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 6,666 | 26,742 (0%) | 0% | - | Ordinary Shares | |
| Kim Dong | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 3,333 | 26,585 (0%) | 0% | - | Ordinary Shares | |
| Drew Jason Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 2,500 | 2,500 | - | - | Restricted Stock Units | |
| Kim Dong | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 3,333 | 6,667 | - | - | Restricted Stock Units | |
| Smith Drew Jason | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 16,500 | 16,500 | - | - | Restricted Stock Units | |
| Kim Dong | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 12,000 | 12,000 | - | - | Restricted Stock Units | |
| Smith Drew Jason | General Counsel | Sale of securities on an exchange or to another person at price $ 15.74 per share. | 31 Jan 2024 | 417 | 18,824 (0%) | 0% | 15.7 | 6,564 | Ordinary Shares |
| Schoenberg Mark | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 3,333 | 153,331 (0%) | 0% | - | Ordinary Shares | |
| Barrett Elizabeth | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 87,615 | 87,615 | - | - | Restricted Stock Units | |
| Schoenberg Mark | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 2,000 | 150,560 (0%) | 0% | - | Ordinary Shares | |
| Smith Drew Jason | General Counsel | Sale of securities on an exchange or to another person at price $ 15.74 per share. | 31 Jan 2024 | 3,328 | 23,414 (0%) | 0% | 15.7 | 52,383 | Ordinary Shares |
| Schoenberg Mark | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.74 per share. | 31 Jan 2024 | 1,894 | 151,437 (0%) | 0% | 15.7 | 29,812 | Ordinary Shares |
| Schoenberg Mark | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 2,000 | 0 | - | - | Restricted Stock Units | |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 834 | 0 | - | - | Restricted Stock Units | |
| Smith Jason Drew | General Counsel | Sale of securities on an exchange or to another person at price $ 15.74 per share. | 31 Jan 2024 | 1,248 | 20,076 (0%) | 0% | 15.7 | 19,644 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 1,333 | 150,756 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.74 per share. | 31 Jan 2024 | 758 | 149,998 (0%) | 0% | 15.7 | 11,931 | Ordinary Shares |
| Drew Jason Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 834 | 19,241 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 1,333 | 1,334 | - | - | Restricted Stock Units | |
| Jason Smith Drew | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 6,666 | 13,334 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.78 per share. | 31 Jan 2024 | 1,137 | 149,423 (0%) | 0% | 15.8 | 17,942 | Ordinary Shares |
| Dong Kim | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 3,333 | 35,253 (0%) | 0% | - | Ordinary Shares | |
| Smith Jason Drew | General Counsel | Sale of securities on an exchange or to another person at price $ 15.78 per share. | 31 Jan 2024 | 417 | 18,824 (0%) | 0% | 15.8 | 6,580 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.78 per share. | 31 Jan 2024 | 758 | 149,998 (0%) | 0% | 15.8 | 11,961 | Ordinary Shares |
| Schoenberg Mark | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.78 per share. | 31 Jan 2024 | 1,894 | 151,437 (0%) | 0% | 15.8 | 29,887 | Ordinary Shares |
| Drew Smith Jason | General Counsel | Sale of securities on an exchange or to another person at price $ 15.78 per share. | 31 Jan 2024 | 1,248 | 20,076 (0%) | 0% | 15.8 | 19,693 | Ordinary Shares |
| Smith Drew Jason | General Counsel | Sale of securities on an exchange or to another person at price $ 15.78 per share. | 31 Jan 2024 | 3,328 | 23,414 (0%) | 0% | 15.8 | 52,516 | Ordinary Shares |
| James A. Robinson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 30,000 | 30,000 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.12 per share. | 31 Jan 2023 | 991 | 147,888 (0%) | 0% | 10.1 | 10,029 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 500 | 147,127 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 2,000 | 148,879 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.12 per share. | 31 Jan 2023 | 661 | 148,560 (0%) | 0% | 10.1 | 6,689 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 500 | 0 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 2,000 | 2,000 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 1,333 | 2,667 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 30,000 | 30,000 | - | - | Employee Stock Option (right to buy) | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.12 per share. | 31 Jan 2023 | 248 | 146,879 (0%) | 0% | 10.1 | 2,510 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 1,333 | 149,221 (0%) | 0% | - | Ordinary Shares | |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 5,000 | 0 | - | - | Restricted Stock Units | |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 13,333 | 13,334 | - | - | Restricted Stock Units | |
| Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 75,000 | 75,000 | - | - | Restricted Stock Units | |
| Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 5,000 | 313,358 (1%) | 0% | - | Ordinary Shares | |
| Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 100,000 | 100,000 | - | - | Performance Stock Units | |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 13,333 | 326,691 (1%) | 0% | - | Ordinary Shares | |
| Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 10.12 per share. | 31 Jan 2023 | 409 | 12,600 (0%) | 0% | 10.1 | 4,139 | Ordinary Shares |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 833 | 13,009 (0%) | 0% | - | Ordinary Shares | |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 2,500 | 15,100 (0%) | 0% | - | Ordinary Shares | |
| Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 10.12 per share. | 31 Jan 2023 | 1,227 | 13,873 (0%) | 0% | 10.1 | 12,417 | Ordinary Shares |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 833 | 834 | - | - | Restricted Stock Units | |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 2,500 | 5,000 | - | - | Restricted Stock Units | |
| Jason Drew Smith | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
| Jason Drew Smith | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) | |
| Dong Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 38,000 | 38,000 | - | - | Employee Stock Option (right to buy) | |
| Dong Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 20 Jan 2023 | 122,677 | 146,627 (0%) | 0% | 5 | 613,385 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2023 | 122,677 | 0 | - | - | Employee Stock Option (right to buy) | |
| Daniel George Wildman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.85 per share. | 31 Oct 2022 | 258 | 23,950 (0%) | 0% | 11.8 | 3,057 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2022 | 500 | 24,208 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2022 | 500 | 500 | - | - | Restricted Stock Units | |
| Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2022 | 15,276 | 0 | - | - | Stock Option (right to buy) | |
| Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2022 | 32,723 | 0 | - | - | Stock Option (right to buy) | |
| Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.94 per share. | 21 Oct 2022 | 47,999 | 1,485,168 (7%) | 0% | 5.9 | 285,114 | Ordinary Shares |
| Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 14 Sep 2022 | 160,000 | 408,693 (1%) | 0% | 5 | 800,000 | Ordinary Shares |
| Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2022 | 160,000 | 0 | - | - | Stock Option (right to buy) | |
| Leana S. Wen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2022 | 3,241 | 0 | - | - | Stock Option (right to buy) | |
| Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 31 Aug 2022 | 3,241 | 248,693 (1%) | 0% | 5 | 16,205 | Ordinary Shares |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2022 | 8,333 | 8,334 | - | - | Restricted Stock Units | |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2022 | 8,333 | 15,782 (0%) | 0% | - | Ordinary Shares | |
| Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 7.21 per share. | 31 Aug 2022 | 3,606 | 12,176 (0%) | 0% | 7.2 | 25,999 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2022 | 500 | 1,000 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2022 | 500 | 23,967 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.81 per share. | 31 Jul 2022 | 259 | 23,708 (0%) | 0% | 7.8 | 2,023 | Ordinary Shares |
| Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 2,211 | 0 | - | - | Stock Option (right to buy) | |
| Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 16 Jun 2022 | 2,211 | 1,437,169 (6%) | 0% | 5 | 11,055 | Ordinary Shares |
| Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Cynthia M. Butitta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Ran Nussbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 3,183 | 3,183 | - | - | Stock Option (right to buy) | |
| Ran Nussbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 6,817 | 6,817 | - | - | Stock Option (right to buy) | |
| Stuart Holden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 06 Jun 2022 | 1,030 | 1,434,958 (6%) | 0% | 5 | 5,150 | Ordinary Shares |
| Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2022 | 1,030 | 0 | - | - | Stock Option (right to buy) | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 500 | 23,721 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 500 | 1,500 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 6.62 per share. | 30 Apr 2022 | 254 | 23,467 (0%) | 0% | 6.6 | 1,681 | Ordinary Shares |
| Dong Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2022 | 30,000 | 30,000 | - | - | Employee Stock Option (right to buy) | |
| Dong Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Molly Henderson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 666 | 5,579 (0%) | 0% | - | Ordinary Shares | |
| Molly Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Molly Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 7,500 | 7,500 | - | - | Restricted Stock Units | |
| Molly Henderson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 666 | 1,334 | - | - | Restricted Stock Units | |
| Molly Henderson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.58 per share. | 31 Jan 2022 | 331 | 5,248 (0%) | 0% | 7.6 | 2,509 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 2,000 | 4,000 | - | - | Restricted Stock | |
| Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 4,000 | 4,000 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 12,064 | 12,064 | - | - | Stock Option (right to buy) | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 500 | 22,595 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.58 per share. | 31 Jan 2022 | 275 | 22,320 (0%) | 0% | 7.6 | 2,085 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 2,000 | 24,320 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.58 per share. | 31 Jan 2022 | 1,099 | 23,221 (0%) | 0% | 7.6 | 8,330 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 500 | 2,000 | - | - | Restricted Stock Units | |
| Elizabeth Barrett | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.58 per share. | 31 Jan 2022 | 5,960 | 308,358 (1%) | 0% | 7.6 | 45,177 | Ordinary Shares |
| Elizabeth Barrett | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.58 per share. | 31 Jan 2022 | 2,235 | 300,985 (1%) | 0% | 7.6 | 16,941 | Ordinary Shares |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 5,000 | 303,220 (1%) | 0% | - | Ordinary Shares | |
| Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 13,333 | 26,667 | - | - | Restricted Stock Units | |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 5,000 | 5,000 | - | - | Restricted Stock Units | |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 13,333 | 314,318 (1%) | 0% | - | Ordinary Shares | |
| Jason Drew Smith | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 833 | 7,863 (0%) | 0% | - | Ordinary Shares | |
| Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 7.58 per share. | 31 Jan 2022 | 414 | 7,449 (0%) | 0% | 7.6 | 3,138 | Ordinary Shares |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 833 | 1,667 | - | - | Restricted Stock Units | |
| Jason Drew Smith | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 7,500 | 7,500 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.09 per share. | 26 Jan 2022 | 111 | 22,095 (0%) | 0% | 8.1 | 898 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2022 | 209 | 0 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2022 | 209 | 22,206 (0%) | 0% | - | Ordinary Shares | |
| Elizabeth Barrett | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 9.15 per share. | 03 Jan 2022 | 46,968 | 298,220 (1%) | 0% | 9.1 | 429,757 | Ordinary Shares |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 105,689 | 0 | - | - | Restricted Stock Units | |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 105,689 | 345,188 (1%) | 0% | - | Ordinary Shares | |
| Molly Henderson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 5,000 | 10,000 | - | - | Restricted Stock Units | |
| Molly Henderson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.03 per share. | 30 Nov 2021 | 2,587 | 4,913 (0%) | 0% | 12.0 | 31,122 | Ordinary Shares |
| Molly Henderson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 5,000 | 7,500 (0%) | 0% | - | Ordinary Shares | |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 8,333 | 10,833 (0%) | 0% | - | Ordinary Shares | |
| Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 8,333 | 16,667 | - | - | Restricted Stock Units | |
| Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 12.03 per share. | 30 Nov 2021 | 3,803 | 7,030 (0%) | 0% | 12.0 | 45,750 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 13.10 per share. | 18 Nov 2021 | 160 | 21,997 (0%) | 0% | 13.1 | 2,096 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 17.16 per share. | 31 Oct 2021 | 258 | 21,837 (0%) | 0% | 17.2 | 4,427 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2021 | 500 | 2,500 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2021 | 500 | 22,095 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.32 per share. | 26 Oct 2021 | 107 | 21,595 (0%) | 0% | 16.3 | 1,746 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Oct 2021 | 208 | 209 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Oct 2021 | 208 | 21,702 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.64 per share. | 31 Jul 2021 | 243 | 21,494 (0%) | 0% | 15.6 | 3,801 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2021 | 500 | 21,737 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2021 | 500 | 3,000 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2021 | 208 | 20,924 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.30 per share. | 26 Jul 2021 | 103 | 20,821 (0%) | 0% | 15.3 | 1,576 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2021 | 208 | 417 | - | - | Restricted Stock Units | |
| Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Cynthia M. Butitta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Kathryn E. Falberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Shawn Cline Tomasello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Stuart Holden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Molly Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Jason Drew Smith | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Molly Henderson | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 15.85 per share. | 17 May 2021 | 2,500 | 2,500 (0%) | 0% | 15.9 | 39,625 | Common Stock |
| Jason Drew Smith | General Counsel | Purchase of securities on an exchange or from another person at price $ 15.71 per share. | 17 May 2021 | 2,500 | 2,500 (0%) | 0% | 15.7 | 39,275 | Common Stock |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 30 Apr 2021 | 243 | 21,132 (0%) | 0% | 20 | 4,860 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2021 | 500 | 21,375 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2021 | 500 | 3,500 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.63 per share. | 26 Apr 2021 | 89 | 20,875 (0%) | 0% | 19.6 | 1,747 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2021 | 209 | 20,964 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2021 | 209 | 625 | - | - | Restricted Stock Units | |
| Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 26 Mar 2021 | 3,241 | 245,452 (1%) | 0% | 5 | 16,205 | Ordinary Shares |
| Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2021 | 3,241 | 0 | - | - | Stock Option (right to buy) | |
| Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2021 | 2,211 | 0 | - | - | Stock Option (right to buy) | |
| Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 25 Mar 2021 | 2,211 | 1,433,928 (6%) | 0% | 5 | 11,055 | Ordinary Shares |
| Ran Nussbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 6,817 | 6,817 | - | - | Stock Option (right to buy) | |
| Ran Nussbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 3,183 | 3,183 | - | - | Stock Option (right to buy) | |
| Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 25 Mar 2021 | 1,030 | 1,431,717 (6%) | 0% | 5 | 5,150 | Ordinary Shares |
| Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2021 | 1,030 | 0 | - | - | Stock Option (right to buy) | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 6,000 | 6,000 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 2,000 | 21,831 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.07 per share. | 02 Feb 2021 | 1,076 | 20,755 (0%) | 0% | 22.1 | 23,747 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Molly Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Molly Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 2,000 | 2,000 | - | - | Restricted Stock Units | |
| Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Jason Drew Smith | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 2,500 | 2,500 | - | - | Restricted Stock Units | |
| Jason Drew Smith | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.12 per share. | 26 Jan 2021 | 100 | 19,831 (0%) | 0% | 22.1 | 2,212 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2021 | 208 | 834 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2021 | 208 | 19,931 (0%) | 0% | - | Ordinary Shares | |
| Elizabeth Barrett | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.51 per share. | 03 Jan 2021 | 2,185 | 240,739 (1%) | 0% | 17.5 | 38,257 | Ordinary Shares |
| Elizabeth Barrett | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.51 per share. | 03 Jan 2021 | 1,240 | 239,499 (1%) | 0% | 17.5 | 21,711 | Ordinary Shares |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2021 | 8,807 | 105,689 | - | - | Restricted Stock Units | |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2021 | 5,000 | 10,000 | - | - | Restricted Stock Units | |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2021 | 8,807 | 237,924 (1%) | 0% | - | Ordinary Shares | |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2021 | 5,000 | 242,924 (1%) | 0% | - | Ordinary Shares | |
| Elizabeth Barrett | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 18.50 per share. | 14 Dec 2020 | 10,000 | 229,117 (1%) | 0% | 18.5 | 185,000 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2020 | 1,042 | 0 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.85 per share. | 04 Dec 2020 | 662 | 19,723 (0%) | 0% | 19.9 | 13,141 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2020 | 1,042 | 20,385 (0%) | 0% | - | Ordinary Shares | |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2020 | 61,652 | 219,117 (1%) | 0% | 0 | Ordinary Shares | |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2020 | 61,652 | 114,496 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Oct 2020 | 208 | 1,042 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.95 per share. | 26 Oct 2020 | 101 | 19,343 (0%) | 0% | 21.0 | 2,116 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Oct 2020 | 208 | 19,444 (0%) | 0% | - | Ordinary Shares | |
| Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.82 per share. | 15 Oct 2020 | 407 | 11,422 (0%) | 0% | 21.8 | 8,882 | Ordinary Shares |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 4,917 | 12,805 (0%) | 0% | - | Ordinary Shares | |
| Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.80 per share. | 15 Oct 2020 | 976 | 11,829 (0%) | 0% | 21.8 | 21,276 | Ordinary Shares |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 2,084 | 2,082 | - | - | Restricted Stock Units | |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 833 | 1,667 | - | - | Restricted Stock Units | |
| Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.72 per share. | 15 Oct 2020 | 1,017 | 10,405 (0%) | 0% | 21.7 | 22,089 | Ordinary Shares |
| Jason Drew Smith | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 25,000 | 25,000 | - | - | Restricted Stock Unit | |
| Jason Drew Smith | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 60,000 | 60,000 | - | - | Employee Stock Option (right to buy) | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.20 per share. | 04 Sep 2020 | 348 | 19,236 (0%) | 0% | 20.2 | 7,030 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2020 | 1,041 | 1,042 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2020 | 1,041 | 19,584 (0%) | 0% | - | Ordinary Shares | |
| Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.82 per share. | 01 Sep 2020 | 509 | 7,888 (0%) | 0% | 22.8 | 11,615 | Ordinary Shares |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 1,042 | 4,166 | - | - | Restricted Stock Units | |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 1,042 | 8,397 (0%) | 0% | - | Ordinary Shares | |
| Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 23.51 per share. | 26 Jul 2020 | 141 | 7,355 (0%) | 0% | 23.5 | 3,315 | Ordinary Shares |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2020 | 417 | 2,500 | - | - | Restricted Stock Units | |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2020 | 417 | 7,496 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2020 | 209 | 18,613 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2020 | 209 | 1,250 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 23.51 per share. | 26 Jul 2020 | 70 | 18,543 (0%) | 0% | 23.5 | 1,646 | Ordinary Shares |
| Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Cynthia M. Butitta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Kathryn E. Falberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Ran Nussbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Shawn Cline Tomasello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Stuart Holden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2020 | 1,042 | 2,083 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2020 | 1,042 | 18,753 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.51 per share. | 04 Jun 2020 | 349 | 18,404 (0%) | 0% | 27.5 | 9,602 | Ordinary Shares |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2020 | 1,041 | 5,208 | - | - | Restricted Stock Units | |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2020 | 1,041 | 7,437 (0%) | 0% | - | Ordinary Shares | |
| Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.07 per share. | 20 May 2020 | 358 | 7,079 (0%) | 0% | 25.1 | 8,975 | Ordinary Shares |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2020 | 35,229 | 157,465 (0%) | 0% | 0 | Ordinary Shares | |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2020 | 35,229 | 176,148 | - | - | Restricted Stock Units | |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2020 | 417 | 6,537 (0%) | 0% | - | Ordinary Shares | |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2020 | 417 | 2,917 | - | - | Restricted Stock Units | |
| Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 24.35 per share. | 26 Apr 2020 | 141 | 6,396 (0%) | 0% | 24.3 | 3,433 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2020 | 208 | 17,781 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2020 | 208 | 1,459 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 24.36 per share. | 26 Apr 2020 | 70 | 17,711 (0%) | 0% | 24.4 | 1,705 | Ordinary Shares |
| Stephen Mullennix | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 24.35 per share. | 26 Apr 2020 | 145 | 10,084 (0%) | 0% | 24.4 | 3,531 | Ordinary Shares |
| Stephen Mullennix | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2020 | 417 | 2,917 | - | - | Restricted Stock Units (RSUs) | |
| Stephen Mullennix | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2020 | 417 | 10,229 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.50 per share. | 04 Mar 2020 | 345 | 17,573 (0%) | 0% | 29.5 | 10,178 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2020 | 1,042 | 3,125 | - | - | Restricted Stock Units | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2020 | 1,042 | 17,918 (0%) | 0% | - | Ordinary Shares | |
| Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 29.68 per share. | 20 Feb 2020 | 360 | 6,120 (0%) | 0% | 29.7 | 10,685 | Ordinary Shares |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2020 | 1,042 | 6,249 | - | - | Restricted Stock Units | |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2020 | 1,042 | 6,480 (0%) | 0% | - | Ordinary Shares | |
| Stephen Mullennix | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 28.04 per share. | 14 Feb 2020 | 612 | 9,812 (0%) | 0% | 28.0 | 17,160 | Ordinary Shares |
| Stephen Mullennix | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2020 | 1,759 | 7,037 | - | - | Restricted Stock Units | |
| Stephen Mullennix | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2020 | 1,759 | 10,424 (0%) | 0% | - | Ordinary Shares | |
| Peter P. Pfreundschuh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2020 | 6,000 | 6,000 | - | - | Restricted Stock Unit | |
| Peter P. Pfreundschuh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2020 | 15,000 | 15,000 | - | - | Stock options (right to buy) | |
| Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2020 | 6,000 | 6,000 | - | - | Restricted stock unit | |
| Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2020 | 15,000 | 15,000 | - | - | Stock options (right to buy) | |
| Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2020 | 15,000 | 15,000 | - | - | Restricted Stock Unit | |
| Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2020 | 45,000 | 45,000 | - | - | Stock options (right to buy) | |
| Stephen Mullennix | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2020 | 15,000 | 15,000 | - | - | Stock options (right to buy) | |
| Stephen Mullennix | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2020 | 3,000 | 3,000 | - | - | Restricted stock unit | |
| Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 29.28 per share. | 26 Jan 2020 | 667 | 4,438 (0%) | 0% | 29.3 | 19,530 | Ordinary Shares |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2020 | 1,666 | 3,334 | - | - | Restricted Stock Units (RSUs) | |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2020 | 1,666 | 5,105 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.15 per share. | 26 Jan 2020 | 322 | 9,177 (0%) | 0% | 29.1 | 9,386 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2020 | 833 | 1,667 | - | - | Restricted Stock Units (RSUs) | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2020 | 833 | 9,499 (0%) | 0% | - | Ordinary Shares | |
| Stephen Mullennix | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 29.26 per share. | 26 Jan 2020 | 684 | 8,665 (0%) | 0% | 29.3 | 20,014 | Ordinary Shares |
| Stephen Mullennix | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2020 | 1,666 | 3,334 | - | - | Restricted Stock Units (RSUs) | |
| Stephen Mullennix | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2020 | 1,666 | 9,349 (0%) | 0% | - | Ordinary Shares | |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2020 | 105,688 | 211,377 | - | - | Ordinary Shares | |
| Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2020 | 105,688 | 122,236 (0%) | 0% | 0 | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2019 | 1,042 | 4,167 | - | - | Restricted Stock Units (RSUs) | |
| Mark Schoenberg | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.69 per share. | 04 Dec 2019 | 343 | 8,666 (0%) | 0% | 31.7 | 10,870 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2019 | 1,042 | 9,009 (0%) | 0% | - | Ordinary Shares | |
| Elizabeth Barrett | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 28.00 per share. | 21 Nov 2019 | 7,530 | 16,548 (0%) | 0% | 28 | 210,840 | Ordinary Shares |
| Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.41 per share. | 20 Nov 2019 | 354 | 3,439 (0%) | 0% | 28.4 | 10,057 | Ordinary Shares |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2019 | 1,042 | 3,793 (0%) | 0% | - | Ordinary Shares | |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2019 | 1,042 | 7,291 | - | - | Restricted Stock Units | |
| Elizabeth Barrett | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 28.00 per share. | 20 Nov 2019 | 7,470 | 9,018 (0%) | 0% | 28 | 209,160 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 28.17 per share. | 19 Nov 2019 | 1,960 | 7,967 (0%) | 0% | 28.2 | 55,213 | Ordinary Shares |
| Elizabeth Barrett | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 26.00 per share. | 15 Nov 2019 | 1,548 | 1,548 (0%) | 0% | 26 | 40,248 | Ordinary Shares |
| Stephen Mullennix | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 26.00 per share. | 14 Nov 2019 | 608 | 7,683 (0%) | 0% | 26.0 | 15,806 | Ordinary Shares |
| Stephen Mullennix | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2019 | 1,759 | 8,796 | - | - | Restricted Stock Units | |
| Stephen Mullennix | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2019 | 1,759 | 8,291 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 33.92 per share. | 04 Sep 2019 | 343 | 6,007 (0%) | 0% | 33.9 | 11,635 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2019 | 1,041 | 5,209 | - | - | Restricted Stock Units (RSUs) | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2019 | 1,041 | 6,350 (0%) | 0% | - | Ordinary Shares | |
| Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.07 per share. | 20 Aug 2019 | 1,416 | 2,751 (0%) | 0% | 33.1 | 46,827 | Ordinary Shares |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2019 | 4,167 | 8,333 | - | - | Restricted Stock Units | |
| Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2019 | 4,167 | 4,167 (0%) | 0% | - | Ordinary Shares | |
| Stephen Mullennix | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2019 | 1,759 | 10,555 | - | - | Restricted Stock Units | |
| Stephen Mullennix | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 31.65 per share. | 14 Aug 2019 | 608 | 6,532 (0%) | 0% | 31.6 | 19,243 | Ordinary Shares |
| Stephen Mullennix | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2019 | 1,759 | 7,140 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2019 | 1,042 | 6,250 | - | - | Restricted Stock Units (RSUs) | |
| Mark Schoenberg | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.05 per share. | 04 Jun 2019 | 343 | 5,309 (0%) | 0% | 35.0 | 12,022 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2019 | 1,042 | 5,652 (0%) | 0% | - | Ordinary Shares | |
| Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2019 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Cynthia M. Butitta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2019 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2019 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Kathryn E. Falberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2019 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Ran Nussbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2019 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Shawn Cline Tomasello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2019 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Stuart Holden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2019 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Stephen Mullennix | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 37.98 per share. | 14 May 2019 | 608 | 5,381 (0%) | 0% | 38.0 | 23,092 | Ordinary Shares |
| Stephen Mullennix | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2019 | 1,759 | 12,314 | - | - | Restricted Stock Units | |
| Stephen Mullennix | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2019 | 1,759 | 5,989 (0%) | 0% | - | Ordinary Shares | |
| Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.02 per share. | 27 Mar 2019 | 128,000 | 212,211 (1%) | 0% | 4.0 | 514,560 | Ordinary Shares |
| Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2019 | 128,000 | 0 | - | - | Stock Option (right to buy | |
| Mark Schoenberg | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 37.01 per share. | 21 Mar 2019 | 272 | 4,610 (0%) | 0% | 37.0 | 10,066 | Ordinary Shares |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2019 | 1,042 | 7,292 | - | - | Restricted Stock Units (RSUs) | |
| Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2019 | 1,042 | 6,329 (0%) | 0% | - | Ordinary Shares | |
| Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.30 per share. | 04 Mar 2019 | 1,991 | 4,338 (0%) | 0% | 37.3 | 74,264 | Ordinary Shares |
| Stephen Mullennix | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2019 | 7,034 | 7,034 (0%) | 0% | - | Ordinary Shares | |
| Stephen Mullennix | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 37.30 per share. | 14 Feb 2019 | 2,804 | 4,230 (0%) | 0% | 37.3 | 104,589 | Ordinary Shares |
| Stephen Mullennix | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2019 | 7,034 | 14,073 | - | - | Restricted Stock Units | |
| Fred E. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2019 | 15,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Fred E. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.99 per share. | 06 Feb 2019 | 15,000 | 15,000 (0%) | 0% | 17.0 | 254,850 | Ordinary Shares |
| Peter P. Pfreundschuh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2019 | 5,000 | 5,000 | - | - | Restricted Stock Unit | |
| Peter P. Pfreundschuh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2019 | 15,000 | 15,000 | - | - | Employee Stock Option (right to buy) | |
| Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2019 | 2,500 | 2,500 | - | - | Restricted Stock Unit | |
| Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2019 | 7,500 | 7,500 | - | - | Employee Stock Option (right to buy) | |
| Stephen Mullennix | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2019 | 15,000 | 15,000 | - | - | Employee Stock Option (right to buy) | |
| Stephen Mullennix | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2019 | 5,000 | 5,000 | - | - | Restricted Stock Unit | |
| Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2019 | 277,432 | 277,432 | - | - | Employee Stock Option (right to buy) | |
| Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2019 | 317,065 | 317,065 | - | - | Restricted Stock Unit |